You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

noncontiguous stage II adult diffuse large cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +71 more
  • Chicago, Illinois
  • +5 more
Oct 8, 2021

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +125 more
  • tetanus-CMV fusion peptide vaccine
  • laboratory biomarker analysis
  • Duarte, California
    City of Hope Medical Center
Feb 28, 2022

Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

Terminated
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
Aug 30, 2021

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma

Completed
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +88 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Apr 14, 2021

Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission

Completed
  • Hematopoietic/Lymphoid Cancer
  • +135 more
  • beclomethasone dipropionate
  • +4 more
  • Hackensack, New Jersey
  • +1 more
Feb 1, 2021

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Lymphoma Trial in Scottsdale, Jacksonville, Rochester (biological, drug, genetic, other)

Active, not recruiting
  • Lymphoma
  • pegfilgrastim
  • +8 more
  • Scottsdale, Arizona
  • +2 more
Jan 7, 2022

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

Recruiting
  • Diffuse Large B Cell Lymphoma，DLBCL
  • PM 8.4 mg/m2
  • PM 11.2 mg/m2
  • Chengdu, Sichuan, China
    West China Hospital Sichuan University
Jan 15, 2023

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

Recruiting
  • The First Affiliated Hospital of Nanchang University
  • Nanchang, Jiangxi, China
  • +1 more
Jul 3, 2023

Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

Terminated
  • Diffuse Large B-cell Lymphoma
  • Tampa, Florida
  • +1 more
Jan 27, 2023

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Dec 12, 2022

Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Jun 24, 2022

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023